Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: The TORPEDO trial at 2 years

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 248, Issue 7, 2010, Pages 943-956

  Spielberg, Leigh ^a   Leys, Anita ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Age related macular degeneration; Choroidal neovascular membrane; Lucentis (ranibizumab injection); Photodynamic therapy; Vascular endothelial growth factor (VEGF)

Indexed keywords

RANIBIZUMAB; VERTEPORFIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE TOXICITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INFLAMMATION; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA EDEMA; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETINA TEAR; SINGLE DRUG DOSE; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 77955665773     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1256-6     Document Type: Article

References (41)

1. Zarbin MA (2004) Current concepts in the pathogenesis of agerelated macular degeneration. Arch Ophthalmol 122:598-614. doi:10.1001/archopht.122.4. 598 122/4/598 [pii] (Pubitemid 38456297)
2. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144:850-857. doi:S0002-9394(07)00718-720 [pii] 10.1016/j.ajo.2007.08. 012 (Pubitemid 350130239)
3. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57-65 e55. doi:S0161-6420(08)01075-1080 [pii] 10.1016/j.ophtha.2008.10.018
4. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY (2006) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 124:1532-1542. doi:124/11/1532 [pii]10.1001/archopht.124.11.1532 (Pubitemid 44748725)
5. Schmidt-Erfurth U, Wolf S (2008) Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 92:1628-1635. doi:bjo.2007.135277 [pii] 10.1136/bjo.2007.135277
6. Kiernan DF, Hariprasad SM, Chin EK, Kiernan CL, Rago J, Mieler WF (2009) Prospective comparison of Cirrus and Stratus optical coherence tomography for quantifying retinal thickness. Am J Ophthalmol 147:267-275 e262. doi:S0002-9394(08)00661-662 [pii] 10.1016/j.ajo.2008.08.018
7. Carpineto P, Nubile M, Toto L, Aharrh Gnama A, Marcucci L, Mastropasqua L, Ciancaglini M (2009) Correlation in foveal thickness measurements between spectral-domain and timedomain optical coherence tomography in normal individuals. Eye. doi:eye200976 [pii] 10.1038/eye.2009.76
8. Cukras C, Wang YD, Meyerle CB, Forooghian F, Chew EY, Wong WT (2009) Optical coherence tomography-based decision making in exudative age-related macular degeneration: comparison of time- vs spectral-domain devices. Eye. doi:eye2009211 [pii] 10.1038/eye.2009.211
9. Durbin M AT, Chang M, Lujan B (2009) Retinal measurements: comparison between Cirrus HD-OCT and Stratus OCT. Zeiss- Meditec White Paper
10. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431. doi:355/14/ 1419 [pii] 10.1056/NEJMoa054481 (Pubitemid 44511557)
11. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444. doi:355/14/1432 [pii] 10.1056/NEJMoa062655 (Pubitemid 44511558)
12. Nishijima K, Ng YS, Zhong L, Bradley J, SchubertW, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171:53-67. doi:171/1/53 [pii]
13. Schlingemann RO (2004) Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 242:91-101. doi:10.1007/s00417-003-0828-0 (Pubitemid 38208289)
14. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239-248. doi:S0002-9394(07)00881-891 [pii] 10.1016/j.ajo.2007.10.004
15. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566- 583. doi:S0002-9394(07)00068-72 [pii] 10.1016/j.ajo.2007.01.028 (Pubitemid 46452533)
16. Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Schmidt-Erfurth U, Wolf S, Markabi S, Schmidli H, Weichselberger A (2009) The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci. doi:iovs.09-3813[pii] 10.1167/iovs.09-3813
17. Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 19:361-372. doi:S0896-1549(06)00054-X [pii] 10.1016/j.ohc.2006.05.009 (Pubitemid 44279358)
18. Spaide R (2007) Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 143:679-680. doi:S0002-9394(07)00190-200 [pii] 10.1016/j.ajo.2007.02.024 (Pubitemid 46452536)
19. Peters S, Julien S, Heiduschka P, Grisanti S, Ziemssen F, Adler M, Schraermeyer U, Bartz-Schmidt KU (2007) Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 91:827-831. doi: bjo.2006.109702 [pii] 10.1136/bjo.2006.109702 (Pubitemid 46846661)
20. Volcker M, Peters S, Inhoffen W, Ziemssen F (2006) Early antiexudative response-OCT monitoring after intravitreal bevacizumab injection. Ophthalmologe 103:476-483. doi:10.1007/ s00347-006-1356-1361
21. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331-335
22. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN (2008) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145:249-256. doi:S0002-9394 (07)00854-859 [pii] 10.1016/j.ajo.2007.09.031
23. Kaiser PK, Blodi BA, Shapiro H, Acharya NR (2007) Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:1868-1875. doi: S0161-6420(07)00467-468 [pii] 10.1016/j.ophtha.2007.04.030 (Pubitemid 47483925)
24. Bradley J, Ju M, Robinson GS (2007) Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10:141-148. doi:10.1007/s10456-007- 9069-x (Pubitemid 46440632)
25. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295. doi:10.1172/JCI17929
26. Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT (2006) Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168:2036-2053. doi:168/6/2036 [pii]
27. D'Amore PA (1994) Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 35:3974-3979
28. Casey R, Li WW (1997) Factors controlling ocular angiogenesis. Am J Ophthalmol 124:521-529
29. Das A, McGuire PG (2003) Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 22:721-748. doi:S135094620300065X [pii]
30. Augustin A, Offerman I (2007) Combination therapy for choroidal neovascularisation. Drugs Aging 24:979-990
31. Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcostegui B, Cunha-Vaz J, Gaudric A, Leys A, Schlingemann RO (2007) Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 85:486-494. doi:AOS979 [pii] 10.1111/j.1600-0420.2007.00979.x (Pubitemid 47163109)
32. Michels S, Schmidt-Erfurth U (2003) Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 44:2147-2154
33. Kaiser PK (2006) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 244:1132-1142. doi:10.1007/s00417-005-0199-9 (Pubitemid 44269592)
34. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473-4480
35. Antoszyk AN, Tuomi L, Chung CY, Singh A (2008) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 145:862-874. doi:S0002-9394(08)00008- 11 [pii]10.1016/j.ajo.2007.12.029
36. Husain D, Kim I, Gauthier D, Lane AM, Tsilimbaris MK, Ezra E, Connolly EJ, Michaud N, Gragoudas ES, O'Neill CA, Beyer JC, Miller JW (2005) Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 123:509-516. doi:123/4/509 [pii] 10.1001/archopht.123.4.509 (Pubitemid 40489924)
37. Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, Immonen I, Lim JI, Menchini U, Naor J, Potter MJ, Reaves A, Rosenfeld PJ, Slakter JS, Soucek P, Strong HA,Wenkstern A, SuXY, Yang YC (2005) Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 123:448-457. doi:123/4/448 [pii] 10.1001/archopht.123.4.448 (Pubitemid 40489914)
38. Singh CN, Saperstein DA (2008) Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration. Retina 28:789-793. doi:10.1097/ IAE.0b013e31817082d7 00006982-200806000-200900001 [pii]
39. Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte TJ, Gragoudas ES (1996) Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidalneovascularization in monkeys. Ophthalmology 13:427-438
40. Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong A, Manjuris U, Gray T, Fsadni M, Bressler NM, Gragoudas ES (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117:1161-1173 (Pubitemid 29428825)
41. Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U (2006) Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 47:371-376. doi:47/1/371 [pii] 10.1167/iovs.05-0354 (Pubitemid 46780838)